Lumicell raises $1 million in a Series B round for its intra-operative cancer-cell detection technology.
Lumicell Diagnostics Inc. hit the $1 million goal for its funding round.
Wellesley, Mass.-based Lumicell is developing a hand-held imaging system designed to give physicians a better picture of the amount of cancer remaining at tumor sites during surgery – oncology surgery’s holy grail of “clean margins.”
The medtech company’s intraoperative imaging system includes a cancer-targeted injectable imaging agent, according to Lumicell’s website. The system is designed to deliver real-time imaging and single-cell detection in a wide field of view during procedures.
